On the 4th December PHARMAQ announced the opening
of a new facility in Kløfta (Norway) for the production of viral antigens for
use in fish vaccines
With the establishment of this state of the art facility, PHARMAQ has now the capacity to produce virus antigen for several hundred million vaccine doses annually and will ensure PHARMAQ’s delivery capacity to the international aquaculture industry for the future.
The plant received authorisation from the Norwegian Medicines Agency on November 1, 2017 and is counting up to twenty five employees.
“Today, we are extremely proud to open this new facility for virus antigen production in Norway” said Morten Nordstad, President PHARMAQ.
“Not only this facility will help secure fish vaccines production for the many years to come, but it also represents a real technological step forward in vaccine production for fish. This new site in Kløfta will ensure close cooperation with our R&D organisation in Oslo and our production facilities for bacterial antigens and finished vaccines in Overhalla.”
Visit the PHARMAQ website, HERE.
The Aquaculturists
This blog is maintained by The Aquaculturists staff and is supported by the
magazine International Aquafeed which is published by Perendale Publishers Ltd
For additional daily news from aquaculture around the world: aquaculture-news
No comments:
Post a Comment